Page 47 - 2021_02-Haematologica-web

Coagulation factor VII, hemostasis and thrombosis
Extensive small-angle X-ray scattering stud- ies of blood coagulation factor VIIa reveal interdomain flexibility Biochemistry. 2010;49(45):9739-9745.
31. Girard TJ, Warren LA, Novotny WF, Bejcek BE, Miletich JP, Broze GJ Jr. Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein. Thromb Res. 1989;55(1):37-50.
32. Hackeng TM, Rosing J. Protein S as cofac- tor for TFPI. Arterioscler Thromb Vasc Biol. 2009;29(12):2015-2020.
33. Broze GJ Jr, Majerus PW. Purification and properties of human coagulation factor VII. J Biol Chem. 1980;255(4):1242-1247.
34.Agersø H, Brophy DF, Pelzer H, et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin follow- ing intravenous administration in hemo- philia patients. J Thromb Haemost. 2011;9(2):333-338.
35.Bernardi F, Castaman G, Pinotti M, et al. Mutation pattern in clinically asympto- matic coagulation factor VII deficiency. Hum Mutat. 1996;8(2):108-115.
36. Gallani D, Wheeler AP, Neff AT. Rare coag- ulation factor deficiencies. In Hoffman et al. Hematology, Basic Principles and Practice. Chapter 137:2034-50. Elsevier, Philadelphia (PA) USA, 2018.
37. Palla R, Peyvandi F, Shapiro A. Rare bleed- ing disorders: diagnosis and treatment. Blood. 2015;125(13):2052-2061.
38. World Federation of Hemophilia. Report on the Annual Global Survey 2017.
39. Abbonizio F, Hassan JH, Riccioni R, Arcieri R, Giampaolo A. National Registry of con- genital bleeding disorders (AICE). Report 2017. Istituto Superiore di Sanità, Rapporti Istisan. 2019,III:54.
40.Bernardi F, Dolce A, Pinotti M, et al. International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost. 2009;7(5):774-779.
41. Di Minno MND, Dolce A, Mariani G on behalf of the STER Study Group. Bleeding symptoms at disease presentation and pre- diction of ensuing bleeding in inherited FVII deficiency. Thromb Haemost. 2013;109(6):1051-1059.
42. Castoldi E, Govers-Riemslag JW, Pinotti M, et al. Coinheritance of factor V (FV) Leiden enhances thrombin formation and is associ- ated with a mild bleeding phenotype in patients homozygous for the FVII 9726þ5G>A (FVII Lazio) mutation. Blood. 2003;102(12):4014-4020.
43. Benlakhl F, Mura T, Schved JK, Giansily- Blaizot M on behalf of the French Study Group of FVII Deficiency. A retrospective analysis of 157 surgical procedures per- formed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost. 2011;152(6):340-346.
44. Giansily-Blaizot M, Verdier R, Biron- Adréani C, et al. Analysis of biological phe- notypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk? Haematologica. 2004;89(6):704-709.
45. Siboni SM, Biguzzi E, Mistretta C, Garagiola L, Peyvandi F. Long-term prophy- laxis in severe FVII deficiency. Haemophilia. 2015;21(6):812-819.
46.Mariani G, Dolce A, Batorova A et al. Recombinant, activated factor VII for sur- gery in factor VII deficiency: a prospective evaluation – the surgical STER. Br J Haematol. 2011;152(3):340-346.
47. Sevenet PO, Kaczor DA, Depasse F. Factor VII deficiency: from basics to clinical labo- ratory diagnosis and patient management. Clin Appl Thromb Hemost. 2017;23 (7):703-710.
48. Cid AR, Lorenzo JI, Haya S, Montoro JM, Casana P, Aznar JA. A comparison of FVII:c and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia. 2001,7(1):39-41.
49. Girolami A, Fabris F, Dal Bo Zanon R, Ghiotto G, Burul A. Factor VII Padua: a congenital coagulation disorder due to an abnormal factor VII with a peculiar activa- tion pattern. J Lab Clin Med. 1978;91(3): 387-395.
50.O'Brien DP, Gale KM, Anderson JS, et al. Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. Blood. 1991;78(1):132- 140.
51. McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EG. Factor VII deficiency and the FVII mutation data- base. Hum Mutat. 2001;17(1):3-17.
52. Ferraresi P, Balestra D, Guittard C, et al. Next-generation sequencing and recombi- nant expression characterized aberrant splicing mechanisms and provided correc- tion strategies in factor VII deficiency. Haematologica. 2020;105(3):829-837.
53. Kemball-Cook G, Johnson DJ, Takamiya O, Banner DW, McVey JH, Tuddenham EG. Coagulation factor VII Gln100 --> Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function. J Biol Chem. 1998;273(14):8516-8521.
54. Andersen E, Chollet ME, Baroni M, et al. The effect of the chemical chaperone 4- phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagula- tion factor FVII. Cell Biosci. 2019;9:69.
55. Toso R, Pinotti M, High KA, Pollak ES, Bernardi F. A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates. Biochem J. 2002;363(Pt 2):411-416.
56. Herrmann FH, Wulff K, Strey R, Siegemund A, Astermark J, Schulman S, International Greifswald Registry of FVII deficiency. Variability of clinical manifestation of fac- tor VII-deficiency in homozygous and het- erozygous subjects of the european F7 gene mutation A294V. Haematologica. 2008;93 (8):1273-1275.
57.Etro D, Pinotti M, Wulff K, et al. The Gly331Ser mutation in factor VII in Europe and the Middle East. Haematologica. 2003;88(12):1434-1436.
58. Pinotti M, Toso R, Redaelli R, Berrettini M, Marchetti G, Bernardi F. Molecular mecha- nisms of FVII deficiency: expression of mutations clustered in the IVS7 donor splice site of factor VII gene. Blood. 1998;92(5):1646-1651.
59. Pinotti M, Rizzotto L, Balestra D, et al. U1- snRNA-mediated rescue of mRNA process- ing in severe factor VII deficiency. Blood. 2008;111(5):2681-2684.
60. Balestra D, Faella A, Margaritis P, et al. An engineered U1 small nuclear RNA rescues splicing defective coagulation F7 gene expression in mice. J Thromb Haemost. 2014;12(2):177-185.
61. Rosen ED, Xu H, Liang Z, Martin JA, Suckow M, Castellino FJ. Generation of genetically-altered mice producing very low levels of coagulation factor VII.
Thromb Haemost. 2005;94(3):493-497.
62. Pavlova A, Preisler B, Driesen J, et al. Congenital combined deficiency of coagu- lation factors VII and X--different genetic mechanisms. Haemophilia. 2015;21(3):386-
391.
63. Branchini A, Ferrarese M, Lombardi S, Mari
R, Bernardi F, Pinotti M. Differential func- tional readthrough over homozygous non- sense mutations contributes to the bleeding phenotype in coagulation factor VII defi- ciency. J Thromb Haemost. 2016;14(10): 1994-2000.
64. Branchini A, Rizzotto L, Mariani G, et al. Natural and engineered carboxy-terminal variants: decreased secretion and gain-of- function result in asymptomatic coagula- tion factor VII deficiency. Haematologica. 2012;97(5):705-709.
65. Toso R, Bernardi F, Tidd T, et al. Factor VII mutant V154G models a zymogen-like form of factor VIIa. Biochem J. 2003;369(Pt 3):563-571.
66. Augustsson C, Persson E. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemo- philia. Blood. 2104;124(20):3172-3174.
67.Morfini M, Batorova A, Mariani G, et al. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large distribution at steady state and a prolonged pharmakodinamic effect. Thromb Haemost. 2014;112(2):424-425.
68. Napolitano M, Giansily-Blaizot M, Dolce A, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica. 2013;98(4):538-544.
69. Kuperman AA, Barg AA, Fructhman Y, et al. Primary prophylaxis for children with severe congenital FVII deficiency. Clinical and laboratory assessment. Blood Cells Mol Dis. 2017;67:86-90.
70. Mariani G, Mannucci PM, Mazzucconi MG, Capitanio A. Treatment of congenital factor VII deficiency with a new concen- trate. Thromb Haemost. 1978;39(3):675- 682.
71. Mariani G, Konkle AB, Kessler CM. Inhibitors in hemophilias. In Hoffman et al. Hematology, Basic Principles and Practice. 5th edition. Chapter 136:2023-33. Elsevier, Philadelphia (PA) USA, 2018.
72. Mariani G, Herrmann FH, Shulman S, et al. Thrombosis in inherited FVII deficiency. J Thromb Haemost. 2003;1(10):2153-2158.
73. Peyvandi F, Garagiola I, Menegatti M. Gynecological and obstetrical manifesta- tions of inherited bleeding disorders in women. J Thromb Haemost. 2011;9(Suppl 1):S236-245.
74. Napolitano M, Di Minno MN, Batorova A, et al. Women with congenital factor VII deficiency: clinical phenotype and treat- ment options from two international stud- ies. Haemophilia. 2016;22(5):752-759.
75. Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood. 2019;133(5):415-424.
76. Bar-Ilan A, Livnat T, Hoffmann M, et al. In vitro characterization of MOD-5014, a novel longacting carboxy-terminal peptide (CTP)- modified activated FVII. Haemophilia. 2018;24(3):477-486.
77. Laros-van Gorkom B, André Holme P, Joch C, et al. Pharmacokinetics and phar- macodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency. Hematology. 2020;25(1):17-25.
haematologica | 2021; 106(2)
361